IMCgp100 + Dacarbazine + Ipilimumab + Pembrolizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Oct 16, 2017 → Sep 17, 2025
NCT ID
NCT03070392About IMCgp100 + Dacarbazine + Ipilimumab + Pembrolizumab
IMCgp100 + Dacarbazine + Ipilimumab + Pembrolizumab is a phase 2 stage product being developed by Immunocore for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03070392. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03070392 | Phase 2 | Completed |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 39 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 29 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 35 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 42 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 39 |
| AEB071 | Novartis | Phase 1 | 29 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 21 |
| DYP688 | Novartis | Phase 1/2 | 36 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 35 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 34 |
| Crizotinib | Pfizer | Phase 2 | 35 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 35 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 24 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 39 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 29 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 35 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 35 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 42 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 27 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 26 |